Glaxo Group Limited

Glaxosmithkline Intellectual Property Development Limited

Leanda Jane Kindon

Panayiotis Alexandrou Procopiou

Nicola Mary Aston

Simon Teanby Hodgson

David George Allen

Naimisha Trivedi

Paul Martin Gore

Caroline Jane Day

Goran Kragol

Darko Filic

Zorica Marusic-Istuk

Christopher David Edlin

Reshma Manesh Chudasama

Julien Bruno Douillet

Rodger Phillip Barnett

Andrew Kennedy

Ashley Paul Hancock

Reshma Chudasama

Franck Patrick Mallet

The compound 3'-N-demethyl-4&#x2033;-O-(2-diethylaminoethanoyl)-6-O-methyl-9a-aza-9a-homoerythromycin A, having the Formula (I): or a salt thereof, compositions comprising the compound, its use in the treatment of neutrophil dominated inflammatory diseases, and methods for its preparation.

Anti-infammatory macrolide

The invention provides N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo [3,4-b]pyridin-5-yl]methyl}-4-({8-[(2-hydroxyethyl) (methyl)amino]octanoyl}amino)benzamide, whose formula is or a salt thereof, such as the monohydrochloride salt thereof. The invention also provides the use of the compound or salt as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, or rhinitis (e.g. allergic and/or non-allergic rhinitis).

Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors

Growing community of inventors

Stevenage, United Kingdom

Leanda Jane Kindon